Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 1;8(5):415-416.
doi: 10.1001/jamacardio.2023.0087.

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

Affiliations
Editorial

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction-Living on the Edge

Alexander T Sandhu et al. JAMA Cardiol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. doi:10.1056/NEJMoa2206286 - DOI - PubMed
    1. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038 - DOI - PubMed
    1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. doi:10.1161/CIR.0000000000001052 - DOI - PubMed
    1. Cohen Laura, et al. Cost-effectiveness of SGLT2 Inhibitors for the Treatment of Heart Failure with Preserved EjectionFraction.
    1. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet Lond Engl. 2022;400(10354):757–767. doi:10.1016/S0140-6736(22)01429-5 - DOI - PubMed